<DOC>
	<DOC>NCT01159587</DOC>
	<brief_summary>The project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A (FVIII &lt; 1%). The observational period will cover at least 5 years per patient. The long-term secondary prophylaxis group will be compared versus on-demand treatment group by the assessment of orthopedic status progression and pharmacoeconomics evaluation.</brief_summary>
	<brief_title>Prophylaxis Versus On-demand Therapy Through Economic Report</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>age ≥ 12 years and ≤ 55 years severe haemophilia A (FVIII &lt; 1%) absence of inhibitors (Bethesda titre &lt; 0.6 BU/ml) Previous Treated Patients (prior exposure days &gt; 200) Kogenate Bayer administered 2030 IU/kg 3 times a week, for the prophylaxis group ≥ 6 joint bleeds requiring treatment with FVIII concentrates in the previous 6 months before enrollment, for ondemand group written informed consent concomitant severe and chronic diseases or congenital skeletal malformation unreliability of patient or likelihood of followup failure presence of inhibitors or history of inhibitors (in the previous 2 years) currently on immune tolerance treatment hepatic cirrhosis or liver disease in rapid progression AIDS platelet count &lt; 75,000/mm3 presence of conditions that influence negatively patient´s compliance participation in another study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>